PI3K/Akt/mTOR inhibitors in breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is frequently activated in breast cancer.
• Preclinical data support targeting this pathway, leading to numerous clinical trials in various cancers, including breast cancer.

Purpose of the Study:

• To review the efficacy and toxicity of PI3K/Akt/mTOR pathway inhibitors from randomized clinical trials.
• To provide guidelines for managing adverse effects associated with these inhibitors.
• To discuss the role of predictive biomarkers in patient selection for mTOR inhibition therapy.

Main Methods:

• Systematic review of randomized clinical trials involving PI3K/Akt/mTOR pathway inhibitors in breast cancer.
• Analysis of efficacy and toxicity data.
• Summary of clinical evidence and expert recommendations.

Main Results:

• Everolimus, an mTOR inhibitor, is approved for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
• Clinical trials show some activity of mTOR inhibition in both HR-positive and HER2-positive breast cancers.
• Benefits of mTOR inhibition may be more significant in selected patient subsets rather than the general breast cancer population.

Conclusions:

• Targeting the PI3K/Akt/mTOR pathway is a viable strategy in breast cancer treatment.
• Effective management of adverse effects and patient/healthcare professional education are crucial for successful treatment.
• Further research into predictive biomarkers is essential to identify patients most likely to benefit from PI3K/Akt/mTOR pathway inhibition.